Copyright © Queen's Printer,

Victoria, British Columbia, Canada

Licence

Disclaimer

Volume 52, No. 5

B.C. Reg. 45/2009

The British Columbia Gazette,

Part II

March 10, 2009

B.C. Reg. 45/2009 , deposited March 2, 2009, pursuant

to the PHARMACISTS, PHARMACY OPERATIONS AND DRUG SCHEDULING ACT

[Section 64]. Order in Council 120/2009, approved and ordered February 27, 2009.

On the recommendation of the undersigned, the Administrator,

by and with the advice and consent of the Executive Council, orders that the

amendments to the Drug Schedules Regulation, B.C. Reg. 9/98, set out in the

schedule to the attached resolution of the Council of the College of Pharmacists

of British Columbia dated June 26, 2008, are approved.

— G. ABBOTT, Minister of Health Services ; S. BOND, Presiding Member

of the Executive Council .

Resolution of the Council of the College of Pharmacists of

British Columbia ("the Council"), made at Vancouver, British Columbia, the 26th

day of June 2008.

RESOLVED THAT:

In accordance with the authority established in

Section 64

of The Pharmacists, Pharmacy Operations and Drug Scheduling Act , R.S.B.C.

1996, c. 363 of British Columbia, the Council amends the Drug Schedules

Regulation as set out in the attached schedule, subject to the approval of the

Lieutenant Governor in Council. — Certified a true copy, Marshall Moleschi,

B.Sc. (Pharm), MHA, Registrar.

Schedule

That the Drug Schedules Regulation be amended by the:

Deletion of:

Benzoyl peroxide (preparations of 5% or less as a single ingredient)

Diclofenac and its salts

Famotidine and its salts (when sold in concentrations of 20 mg or

less per oral dosage unit and indicated for the treatment of heartburn, in

package sizes containing more than 600 mg of famotidine)

Levonorgestrel (when sold in concentrations of 0.75 mg per oral

dosage unit, packaged and labelled for emergency contraception)

and the addition of:

Abatacept

Calcium salts when sold for the treatment of hyperphosphatemiav

Deracoxib

Diclofenac and its salts, except when sold as a single medicinal

ingredient in a concentration

equivalent of 1% or less diclofenac in preparations for topical use on the

skin

Diclofenac diethylamine (in preparations for topical use on the skin in

concentrations of not more

than 1% diclofenac)

Entecavir

Erlotinib and its salts

Famotidine and its salts (when sold in concentrations of 20 mg or less per

oral dosage unit and

indicated for the treatment of heartburn, in package sizes containing more

than 600 mg of

famotidine)

Histrelin and its salts

Lanthanum salts (when sold for the treatment of hyperphosphatemia)

Levonorgestrel when sold in concentrations of 0.75 mg per oral dosage unit

(except when labelled

to be taken as a single dose of 1.5 mg and in package sizes containing no

more than 1.5 mg

levonorgestrel, packaged and labelled for emergency contraception)

Levonorgestrel (when sold in concentrations of 0.75 mg per oral dosage

unit to be taken as a single

dose of 1.5 mg, packaged and labelled for emergency contraception, in

package sizes containing no

more than 1.5 mg of levonorgestrel)

Lutropin alfa

Pregabalin and its salts and derivatives

Resocortol and its derivatives

Solifenacin and its salts

Sunitinib and its salts

Trospium chloride

Copyright © 2009: Queen's Printer, Victoria, British Columbia, Canada